HQL
Tekla Life Sciences Investors
NYSE · Financial Services · Asset Management · US
$20.64
−0.34%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 79.8M | 86.4M | 86.7M | 39.4M | 31.9M |
| Cost of Revenue | 10.9M | 5.0M | 5.4M | 5.2M | 5.5M |
| Gross Profit | 71.7M | 86.4M | 86.7M | 18.3M | 26.3M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | (3.28) |
| SG&A Expense | 9.9M | 743.2K | 1.3M | 903.1K | 1.1M |
| General & Admin Expense | 9.9M | 743.2K | 1.3M | 903.1K | 1.1M |
| Selling & Marketing Expense | 26.1K | — | — | — | — |
| Other Expenses | (148.1M) | 48.4K | 56.7K | 268.3K | 276.0K |
| Total Operating Expenses | (77.9M) | 791.6K | 1.4M | 1.2M | 1.4M |
| Cost and Expenses | (69.9M) | 791.6K | 1.4M | 17.0M | 136.5M |
| Operating Income (EBIT) | 149.7M | 85.6M | 85.3M | (5.2M) | (104.6M) |
| Non-Operating | |||||
| Interest Income | 883.0K | 349.8K | 1.0M | 204.4K | 50.1K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 883.0K | 349.8K | 1.0M | 204.4K | 50.1K |
| Other Non-Op Income/Expense | (9.6M) | — | 87.2M | 27.6M | 2.4K |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 186.0M | 85.6M | 85.3M | 22.4M | (104.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | 186.0M | 85.6M | 85.3M | 22.4M | (104.6M) |
| Earnings from Cont. Ops | 186.0M | 85.6M | 85.3M | 22.4M | (104.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 186.0M | 85.6M | 85.3M | 22.4M | (104.6M) |
| Per Share | |||||
| Basic EPS | $6.33 | $2.96 | $3.04 | $0.79 | ($4.07) |
| Diluted EPS | $6.33 | $2.96 | $3.04 | $0.79 | ($4.07) |
| Revenue Per Share | $2.62 | $2.99 | $3.09 | $1.39 | $1.24 |
| Shares | |||||
| Basic Shares Outstanding | 30.4M | 28.9M | 28.1M | 28.3M | 25.7M |
| Diluted Shares Outstanding | 30.4M | 28.9M | 28.1M | 28.3M | 25.7M |
| Profitability Metrics | |||||
| EBITDA | 186.0M | 85.6M | 87.2M | 50.0M | (101.6M) |
| D&A | 2.6M | — | 1.9M | 27.6M | 3.0M |
| EBIT | 149.7M | 85.6M | 85.3M | 22.4M | (104.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026